UTI − quo vadis? New alternatives to treat uncomplicated urinary tract infections

Abstract

Urinary tract infections (UTI) are one of the most common problems in urology clinics. The European Association of Urology (EAU) has been pioneering in its efforts to disseminate the latest clinical findings through the organization of the annual EAU congresses. At this year's congress (EAU Barcelona 2019), various satellite symposia were organized, focusing on specific issues in the field of urology. "UTI − quo vadis? New alternatives to treat uncomplicated urinary tract infections" was one of the industry-sponsored symposia, organized with the aim of evaluating the current scenario and also throwing light on the paradigm shift in the treatment of acute, uncomplicated lower urinary tract infections (uUTI). Several interlinking topics were presented during this symposium. The topics covered antibiotic resistance, involving a presentation of the current data from the Global Prevalence Study on Infections in Urology (GPIU-study). This discussion was followed by case reports on the impact of antibiotic resistance on the management of patients with UTI/uUTI and treatment options for UTI/uUTI according to current guidelines. The highlight of the symposium was the presentation of very recent data from a gold standard phase III clinical trial (double-blind, double-dummy randomized study), demonstrating the non-inferiority of a herbal medicine (BNO 1045) versus antibiotic therapy (fosfomycin trometamol (FT), as a single dose = 3 g) for the treatment of acute, uncomplicated cystitis.

Review of the Phytoneering Research & Experience Summit (PRES) 2019 “building bridges between nature’s healing potential and evidence-based medicine - 20 years of phytoneering”

“…On the other hand, collateral damage, epidemiologic side effects of antibiotics and the severe impact of typical antibiotics on the microbiome are increasingly reported [10]. Several studies with pain medication (ibuprofen and diclofenac, respectively) versus antibiotics (fosfomycin, pivmecillinam and norfloxacin, respectively) came to the conclusion that symptomatic therapy with NSAIDs alone was successful [11], however, the symptoms resolved faster under antibiotic therapy.…”

“…The latest addition to the Sinupret® brand was Sinupret® extract in 2012, using cutting-edge extraction techniques to increase the content of active ingredients without changing the size of the tablet. In his presentation, Prof. Bachert highlighted milestones of Sinupret's success story, including preclinical pharmacological data and high-quality clinical studies he personally conducted with his colleagues [11,12]. All of this made it possible to develop Sinupret® from an experience-based remedy into an evidence-based phytomedicine, recommended in several national and international rhinosinusitis guidelines.…”